Literature DB >> 19563094

Antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus isolates from South Africa.

E Marais1, N Aithma, O Perovic, W F Oosthuysen, E Musenge, A G Dusé.   

Abstract

OBJECTIVE: Trends in the antibiotic susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) are regularly investigated in many countries, but minimal countrywide data are available for South Africa. The aim of this study was to describe the antibiotic susceptibility patterns of MRSA isolates collected in South Africa.
DESIGN: Susceptibility testing of 248 MRSA isolates collected from 15 National Health Laboratory Services (NHLS) and 8 private laboratories against 17 antibiotics was performed using the disc diffusion method. Demographic data were collected and correlated with antibiotic resistance patterns.
RESULTS: Antibiotic resistance of MRSA to erythromycin, tetracycline, trimethoprim/sulfamethoxazole, gentamicin and ciprofloxacin ranged between 55% and 78%, while all isolates were susceptible to teicoplanin, linezolid, vancomycin and quinopristin/dalfopristin. A significant difference in the resistance pattern of the isolates towards certain antimicrobial agents was identified among adults and children, as well as between isolates collected from the private and NHLS laboratories.
CONCLUSION: This is the first extensive report on the antimicrobial susceptibilities of South African MRSA isolates. These data can assist treatment decisions and form a baseline for further surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563094

Source DB:  PubMed          Journal:  S Afr Med J


  16 in total

1.  Molecular characterization of clinical methicillin-resistant Staphylococcus aureus isolates in South Africa.

Authors:  A Moodley; W F Oosthuysen; A G Dusé; E Marais
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

2.  Methicillin-resistant Staphylococcus aureus in Zimbabwe.

Authors:  Kathrine Mauchaza; Farai D Madzimbamuto; Seymour Waner
Journal:  Ghana Med J       Date:  2016-06

3.  High prevalence of multiple-antibiotic-resistant (MAR) Escherichia coli in river bed sediments of the Apies River, South Africa.

Authors:  Akebe Luther King Abia; Eunice Ubomba-Jaswa; Maggy Ndombo Benteke Momba
Journal:  Environ Monit Assess       Date:  2015-09-30       Impact factor: 2.513

4.  ASSOCIATION OF HIV WITH BREAST ABSCESS AND ALTERED MICROBIAL SUSCEPTIBILITY PATTERNS.

Authors:  Bernard Kapatamoyo; Benjamin Andrews; Kasonde Bowa
Journal:  Med J Zambia       Date:  2010

5.  Warfarin-induced skin necrosis in HIV-1-infected patients with tuberculosis and venous thrombosis.

Authors:  F Bhaijee; H Wainwright; G Meintjes; R J Wilkinson; G Todd; E De Vries; D J Pepper
Journal:  S Afr Med J       Date:  2010-06-01

6.  Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP).

Authors:  Julie R Harris; Barbara J Marston; Nalinee Sangrujee; Desiree DuPlessis; Benjamin Park
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

7.  Genetic basis of rifampicin resistance in methicillin-resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa.

Authors:  Melissa J Jansen van Rensburg; Andrew C Whitelaw; Brenda G Elisha
Journal:  BMC Microbiol       Date:  2012-03-26       Impact factor: 3.605

8.  Multiple-locus VNTR Analyses of Methicillin-resistant Staphylococcus aureus from Jamaica.

Authors:  Paul D Brown
Journal:  Infect Dis (Auckl)       Date:  2015-09-23

9.  Epidemiology of Staphylococcus aureus bacteraemia at a tertiary children's hospital in Cape Town, South Africa.

Authors:  Reené Naidoo; James Nuttall; Andrew Whitelaw; Brian Eley
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

10.  Low prevalence of methicillin resistant Staphylococcus aureus as determined by an automated identification system in two private hospitals in Nairobi, Kenya: a cross sectional study.

Authors:  Geoffrey Omuse; Beatrice Kabera; Gunturu Revathi
Journal:  BMC Infect Dis       Date:  2014-12-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.